SCHEMBL4179499

SCHEMBL4179499

O=C(O)c1ccc(-c2ncccc2Cl)cc1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.51
TDP1 Q9NUW8 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.49
LMNA P02545 1/20 0.49
RORB Q92753 1/20 0.48
TSHR P16473 2/20 0.47
CASP1 P29466 1/20 0.47
ALDH1A1 P00352 2/20 0.46
XDH P47989 1/20 0.46
PDK1 Q15118 3/20 0.45
PDK2 Q15119 3/20 0.45
PDK3 Q15120 3/20 0.45
PDK4 Q16654 3/20 0.45
MKNK1 Q9BUB5 1/20 0.44
MKNK2 Q9HBH9 1/20 0.44
PKM P14618 1/20 0.44
NTRK1 P04629 1/20 0.44
KMO O15229 2/20 0.43
TRPV1 Q8NER1 2/20 0.43
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4809441 0.87 KDM4E (0.47) KDM4ETDP1SMN1; SMN2LMNARORB
SCHEMBL4182257 0.87 KDM4E (0.47) KDM4ETDP1SMN1; SMN2LMNARORB
SCHEMBL4816413 0.83 DPP4 (0.46) KDM4ETDP1SMN1; SMN2LMNARORB
SCHEMBL4805652 0.83 ACLY (0.47) KDM4ETDP1SMN1; SMN2LMNARORB
SCHEMBL4188954 0.83 RORC (0.53) PDK1PDK2PDK3PDK4KMO
SCHEMBL3874091 0.79 TRPV1 (0.56) KDM4ETDP1SMN1; SMN2LMNAMKNK1
SCHEMBL4812253 0.78 ACLY (0.57) KDM4EALDH1A1MKNK2L3MBTL1MEN1
SCHEMBL4184573 0.78 TSHR (0.56) SMN1; SMN2TSHRCASP1ALDH1A1XDH
SCHEMBL4178497 0.78 DHODH (0.56) KDM4ESMN1; SMN2LMNATSHRCASP1
SCHEMBL2770320 0.77 TSHR (0.68) KDM4ESMN1; SMN2TSHRCASP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9199965-B2 Benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG CO., LTD. (KR) 2015-12-01 US disclosed
EP-1861387-B1 BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF DAE WOONG PHARMA (KR) 2014-04-16 EP disclosed
CN-101128452-B Novel benzimidazole derivatives and pharmaceutical compositions containing the same DAE WOONG PHARMA 2012-11-21 CN disclosed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US disclosed
CN-101128452-A Novel benzimidazole derivatives and pharmaceutical compositions containing the same DAE WOONG PHARMA (KR) 2008-02-20 CN disclosed
EP-1861387-A1 NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2007-12-05 EP disclosed
WO-2006080821-A1 NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2006-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same TRPV1, TRPA1, BDKRB2 KDM4E 4596/4885TDP1 3100/4885SMN1; SMN2 1331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.